Bristol-Myers Squibb & BioMotiv to develop new innovative therapies

A new partnership between BioMotiv and Bristol-Myers Squibb (BMS) will see both parties develop new innovative therapies for patients that need the most.

Under the terms of the strategic partnership, BMS will become a limited partner of BioMotiv with the option to invest additional funding in selected projects of mutual interest.

Both parties will form and fund new companies to develop novel therapeutics in disease areas where unmet medical needs remain.

Upon the identification of a preclinical candidate molecule, BMS will have the option to acquire the company from BioMotiv under pre-agreed terms.

“This new partnership effectively pairs two organisations with a mission – to translate transformational discoveries into breakthrough therapies for patients living with serious diseases,” said Satish Jindal, BioMotiv’s Managing Director.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news